CN Patent

CN101959519B — 用于玻璃体内注射的低粘度、高度絮凝的曲安奈德混悬液

Assigned to Novartis AG · Expires 2013-03-20 · 13y expired

What this patent protects

本发明公开了曲安奈德混悬液组合物。该混悬液组合物具有相对低的粘度并易于通过27-或30-号注射针头压出，但它是高度絮凝的并容易再分散。该组合物特别适合于玻璃体内注射。

USPTO Abstract

本发明公开了曲安奈德混悬液组合物。该混悬液组合物具有相对低的粘度并易于通过27-或30-号注射针头压出，但它是高度絮凝的并容易再分散。该组合物特别适合于玻璃体内注射。

Drugs covered by this patent

Patent Metadata

Patent number
CN101959519B
Jurisdiction
CN
Classification
—
Expires
2013-03-20
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.